61291. Group Leader
Session: Poster Discussion Round: Clostridium difficile
Saturday, October 29, 2016: 12:00 AM
Room: Poster Hall
Dale N. Gerding, MD, FIDSA, FSHEA, MACP, Medicine, Edward Hines Jr. VA Hospital, Hines, IL


Disclosures:

D. N. Gerding, Rebiotix: Board Member , Consulting fee
Merck: Board Member , Consulting fee
Actelion: Board Member , Consulting fee
Da Volterra: Consultant , Consulting fee
MGB: Consultant , Consulting fee
Pfizer: Consultant , Consulting fee
Sanofi Pasteur: Consultant , Consulting fee
Summit: Board Member , Consulting fee
ViroPharma Shire: Consultant and Patent licensee , Consulting fee
Seres Therapeutics: Research Contractor , Research grant

See more of: Clostridium difficile
See more of: Poster Discussion Round

Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.